Drugs / MET
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05316935 | Jul 2022 → Mar 2028 expected | atypical endometrial hyperplasia, endometrium neoplasm, progesterone resistance | Xiaojun Chen | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MET | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05316935 ↗ |
| Route | Oral | “500mg po tid” NCT05316935 ↗ |